ITP affects about 5 people per 10,000. It can be associated with other conditions that are hematologic (leukemia) or ...

Q: My platelets were slightly elevated on my blood test. What can cause this? A: Platelets are part of how our body forms clots to stop bleeding. They are produced in the bone marrow by cells called ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

Medically reviewed by Douglas A. Nelson, MD Key Takeaways A high platelet count can lead to mild bruising or serious ...

Dear Dr. Roach: My husband was diagnosed with chronic lymphocytic leukemia (CLL) in 2010 and remained in stage 2 with no effects until 2022. In the interim, he was also diagnosed with atrial ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...

The state’s blood platelet shortage is improving after last week’s low point — which reached Bloodworks Northwest’s “critical” category — but thousands of donations are still needed. Bloodworks ...

September 20, 2007 — Human immunodeficiency virus (HIV)-infected patients with declining platelet counts appear to be at increased risk for HIV-associated dementia (HIV-D), a new study suggests.

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune thrombocytopenia, according to randomized phase 3 study results.The combination ...